On January 19, 2024, Safety Shot, Inc. received a letter from the United States Securities and Exchange Commission (SEC) regarding Post-Effective Amendment No. 4 to its Form S-1, which was filed on January 12, 2024. The SEC conducted a limited review and issued several comments requiring Safety Shot to file a post-effective amendment with additional information. The SEC's comments addressed concerns about the company's disclosure of its brand's standards of excellence, liquidity and capital resources, known trends affecting liquidity, product sales, inventory write-offs, revenue generation, and the development and commercialization status of its products, including Safety Shot, SS-100, Photocil, JW-700, JW-500, and NoStingz. The SEC specifically requested clarification on the basis of the company's brand excellence claims, trends...Show More

On January 19, 2024, Safety Shot, Inc. received a letter from the United States Securities and Exchange Commission (SEC) regarding Post-Effective Amendment No. 4 to its Form S-1, which was filed on January 12, 2024. The SEC conducted a limited review and issued several comments requiring Safety Shot to file a post-effective amendment with additional information. The SEC's comments addressed concerns about the company's disclosure of its brand's standards of excellence, liquidity and capital resources, known trends affecting liquidity, product sales, inventory write-offs, revenue generation, and the development and commercialization status of its products, including Safety Shot, SS-100, Photocil, JW-700, JW-500, and NoStingz. The SEC specifically requested clarification on the basis of the company's brand excellence claims, trends impacting liquidity, details on reduced sales and inventory write-offs, and the current status of product development and commercialization. Additionally, the SEC highlighted the need for Safety Shot to revise statements regarding the safety and efficacy of its products that have not been approved by the FDA or similar foreign regulators, and to discuss the regulatory approvals for each product. The SEC also asked for the timing of the company's plans to file an IND application with the FDA for SS-100 and the significance of the Institutional Review Board's approval of a prospective study.